Organogenesis Holdings Past Earnings Performance
Past criteria checks 2/6
Organogenesis Holdings has been growing earnings at an average annual rate of 39.7%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been growing at an average rate of 14% per year. Organogenesis Holdings's return on equity is 2.1%, and it has net margins of 1.3%.
Key information
39.7%
Earnings growth rate
45.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 14.0% |
Return on equity | 2.1% |
Net Margin | 1.3% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Jun 10Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
May 21Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
May 01Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio
Oct 18Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Organogenesis gets FDA clearance for PuraPly MZ for wound healing
Aug 15Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors
Jul 28Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Organogenesis Holdings: What Now
May 18The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet
Mar 31These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Mar 04Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly
Nov 30Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Could Be 24% Above Their Intrinsic Value Estimate
Sep 27Revenue & Expenses Breakdown
How Organogenesis Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 435 | 6 | 266 | 46 |
31 Dec 23 | 433 | 5 | 266 | 44 |
30 Sep 23 | 449 | 13 | 277 | 44 |
30 Jun 23 | 457 | 10 | 287 | 43 |
31 Mar 23 | 461 | 13 | 290 | 42 |
31 Dec 22 | 451 | 16 | 282 | 40 |
30 Sep 22 | 463 | 59 | 273 | 37 |
30 Jun 22 | 460 | 71 | 259 | 36 |
31 Mar 22 | 462 | 83 | 254 | 33 |
31 Dec 21 | 467 | 94 | 249 | 31 |
30 Sep 21 | 446 | 62 | 236 | 29 |
30 Jun 21 | 433 | 69 | 226 | 24 |
31 Mar 21 | 379 | 43 | 209 | 21 |
31 Dec 20 | 338 | 17 | 203 | 20 |
30 Sep 20 | 306 | -5 | 203 | 17 |
30 Jun 20 | 270 | -37 | 201 | 18 |
31 Mar 20 | 266 | -42 | 203 | 17 |
31 Dec 19 | 261 | -39 | 200 | 15 |
30 Sep 19 | 250 | -46 | 192 | 14 |
30 Jun 19 | 236 | -48 | 181 | 13 |
31 Mar 19 | 215 | -58 | 168 | 11 |
31 Dec 18 | 193 | -65 | 158 | 11 |
30 Sep 18 | 183 | -60 | 150 | 10 |
30 Jun 18 | 184 | -52 | 147 | 10 |
31 Mar 18 | 187 | -32 | 142 | 10 |
31 Dec 17 | 199 | -9 | 134 | 9 |
31 Dec 16 | 139 | -17 | 93 | 6 |
31 Dec 15 | 99 | -24 | 74 | 4 |
Quality Earnings: ORGO has high quality earnings.
Growing Profit Margin: ORGO's current net profit margins (1.3%) are lower than last year (2.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORGO has become profitable over the past 5 years, growing earnings by 39.7% per year.
Accelerating Growth: ORGO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ORGO had negative earnings growth (-56.9%) over the past year, making it difficult to compare to the Biotechs industry average (-14.4%).
Return on Equity
High ROE: ORGO's Return on Equity (2.1%) is considered low.